Thursday, October 25, 2012

Another Unknown Weapon Available for CHIR-258 cancer research

No dose of dasatinib or delivery issue tested provided any survival benefit to the mice compared to PBS controls. To investigate the capacity of dasatinib to restrict dissemination, mice were implanted with osmotic pumps for delivery of medicines and then challenged with sublethal inocula of VacV IHD J Concentrations tested ranged
 in between .

05 and 240 mg/kg/day. After 4 days, the ovaries had been removed, and viral genome copies were quantified by quantitative PCR. The data indicated that none of the doses of dasatinib inside the range tested drastically minimize viral loads in mice. During postmortem examination, spleens of mice taken care of with dasatinib appeared significantly diminished in weight relative

No comments:

Post a Comment